Brainstorm Cell Therapeutics Inc.
BCLI
$0.69
$0.00-0.29%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.05% | -42.69% | -29.47% | 17.98% | -52.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.63% | -32.84% | -13.72% | 24.86% | -33.62% |
| Operating Income | 29.63% | 32.84% | 13.72% | -24.86% | 33.62% |
| Income Before Tax | 18.13% | 22.23% | -14.25% | 15.79% | 46.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.13% | 22.23% | -14.25% | 15.79% | 46.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.13% | 22.23% | -14.25% | 15.79% | 46.70% |
| EBIT | 29.63% | 32.84% | 13.72% | -24.86% | 33.62% |
| EBITDA | 29.97% | 33.12% | 13.57% | -26.02% | 33.81% |
| EPS Basic | 57.72% | 62.49% | 37.07% | 42.69% | 67.92% |
| Normalized Basic EPS | 57.73% | 62.48% | 37.07% | 42.70% | 67.92% |
| EPS Diluted | 57.72% | 62.49% | 37.07% | 42.69% | 67.92% |
| Normalized Diluted EPS | 57.73% | 62.48% | 37.07% | 42.70% | 67.92% |
| Average Basic Shares Outstanding | 93.66% | 107.31% | 81.57% | 46.95% | 66.14% |
| Average Diluted Shares Outstanding | 93.66% | 107.31% | 81.57% | 46.95% | 66.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |